View Post

Puma Biotechnology Announces Top Line Results of the Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

SOURCE: Puma Biotechnology, Inc. From: apnews.com Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced top line results from the Phase III NALA trial of the Company’s lead drug candidate PB272 (neratinib) in patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments (third-line disease) in the setting of metastatic disease. The Phase …

View Post

Todos Medical Presents Encouraging Scientific Abstract

In Clinical Trials by Barbara Jacoby

Source: Todos Medical Ltd. From: apnews.com Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer, presented its scientific abstract discussing the most recent clinical trial results of the TM-B1 cancer screen test at the 2018 San Antonio Breast Cancer Symposium (SABCS) earlier today. The TM-B1 cancer …

View Post

CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer

In Clinical Trials by Barbara Jacoby

From: globenewswire.com CytoDyn Inc. (OTCQB:CYDY), a biotechnology company developing  a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, including metastatic cancers, human immunodeficiency virus (HIV) and graft-versus-host disease (GvHD) is pleased to announce that on November 23, 2018, it received FDA approval of its IND submission and is allowed to initiate a phase 1b/2 clinical trial for metastatic triple-negative breast …

View Post

Generon Presented Positive Phase III Results From a Double-Blind, Placebo Controlled-Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy

In Clinical Trials by Barbara Jacoby

From: apnews.com Dec 8, 2018–Generon BioMed Holding Ltd. (Generon), announced today at the annual San Antonio Breast Cancer Symposium (SABCS), positive results from a placebo-controlled trial with F-627, a recombinant human Granulocyte Colony Stimulating Factor (rhG-CSF) protein, designed using Generon’s Dikine TM technology platform. Led by Principle Investigator Dr. John Glaspy, Estelle, Abe and Marjorie Endowed Chair in Cancer Research …

View Post

Trials Answer Questions About Duration of Treatment in HER2+ Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Angelica Welch From: oncnursingnews.com The optimal duration of treatment for patients with HER2-positive breast cancer has been called into question by recent findings from the NSABP B-52, PERSEPHONE, and APT clinical trials. Priya Rastogi, MD, senior associate medical director, NSABP Medical Affairs, associate professor of Medicine, University of Pittsburgh, shed light on the subject during a presentation she gave …

View Post

Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

In Clinical Trials by Barbara Jacoby

From: businesswire.com Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, is presenting updated results from a Phase II clinical trial of Puma’s drug neratinib at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas. The presentation entitled, “The impact of neratinib with or without anti-diarrheal prophylaxis on health-related quality of life in …

View Post

New Clinical Trial for Triple-Negative Breast Cancer at Sylvester Comprehensive Cancer Center

In Clinical Trials by Barbara Jacoby

Vaccine Designed to Prevent Recurrence Panic washed over Jackie Barrett when she first received her breast cancer diagnosis. “My eyes went dark. I couldn’t hear anything. It was like a train was coming at me,” she says. Jackie’s oncologist explained that her type of breast cancer is called triple-negative because it does not have receptors for estrogen, progesterone or the …

View Post

UCSF-led clinical trial model may present a better way to test new breast cancer drugs

In In The News by Barbara Jacoby

By Josh Baxt From: medcitynews.com Clinical trials have a long rap sheet: expensive, slow, inaccurate, prone to failure. Patients, researchers, and investors wait impatiently for that elusive signal to show up – often in vain. But now, a UC San Francisco-led group may be developing a better way. Their solution is a platform trial called I-SPY – which stands for Investigating …

View Post

FDA Approves Pembrolizumab for Pancreatic Cancers with Mismatch Repair Deficiency

In In The News by Barbara Jacoby

Source: The Lustgarten Foundation for Pancreatic Cancer Research From: PR Newswire In an unprecedented, fast-tracked review, the Food and Drug Administration (FDA) approved the use of pembrolizumab (anti-PDI) immunotherapy for patients with advanced pancreatic cancers who have a defect in their capacity to repair DNA.  Support from the Lustgarten Foundation was critical to the success of the clinical trial that …

View Post

Stage four cancer now undetectable in man after trial treatment

In In The News by Barbara Jacoby

by CNN Wire From: myfox8.com A Phoenix man with pancreatic cancer, who was told he only had months to live, says he has been given a second chance at life. Phil Zeblisky, a 57-year-old, says doctors at two cancer centers considered his stage four pancreatic cancer a death sentence. “When you’re given that kind of diagnosis, you need to put …